LLY - ELI LILLY & Co
Close
765.55
-1.335 -0.174%
Share volume: 112,297
Last Updated: Mon 06 Jan 2025 08:30:05 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$766.88
-1.34
-0.17%
Fundamental analysis
71%
Profitability
90%
Dept financing
25%
Liquidity
50%
Performance
70%
Performance
5 Days
0.50%
1 Month
-5.41%
3 Months
-12.96%
6 Months
-14.82%
1 Year
24.91%
2 Year
115.46%
Key data
Stock price
$765.55
DAY RANGE
$764.46 - $783.20
52 WEEK RANGE
$623.88 - $972.53
52 WEEK CHANGE
$24.91
DIVIDEND
$1.30
EX-DIVIDEND DATE
08/15/2024
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lilly.com
Employees: 39,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news